Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) ( NEO: BMND ) ( OTC: BMNDF ) ( FSE: 3XI ), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, today announced the results of matters voted on at its annual and special meeting of holders of common shares (“ Shareholders ”) held on Wednesday, June 28, 2023 (the “ Meeting ”). The voting results for each of the matters presented at the Meeting are outlined below.

There were 21 Shareholders represented virtually or by proxy at the Meeting holding 34,475,572 common shares, representing 46.11% of Biomind’s total issued and outstanding common shares as at the record date for the Meeting. As the Meeting was held virtually, all resolutions were passed by a ballot vote.

1. Appointment of Auditor

MNP LLP, Chartered Professional Accountants, was appointed as auditor of Biomind until the next annual meeting of the holders of the Shareholders at remuneration to be fixed by the directors. Voting results are as set out below:

2. Election of Directors

Each of the nominees for election as directors were elected as directors of Biomind for the ensuing year or until their successors are elected or appointed. Voting results for the election of the individual directors are as set out below:

3. Share Consolidation

The special resolution was passed approving matters related to a consolidation of the common shares by a ratio of up to 10:1, as more fully described in the management information circulate dated May 31, 2023. Voting results are as set out below:

About Biomind Labs Inc.

Biomind Labs is a biotech research and development company aimed at transforming biomedical sciences knowledge into novel pharmaceutical drugs and innovative nanotech delivery systems for a variety of psychiatric and neurological conditions. Through its acceleration platform, Biomind Labs is developing novel pharmaceutical formulations of N, N-dimethyltryptamine (“ DMT ”), 5-MeO-DMT and mescaline for treating a wide range of therapeutic indications. Biomind Labs’ focus is to provide patients access to affordable and modern-day treatments.

The Neo Exchange Inc. has neither approved nor disapproved the contents of this news release and is not responsible for the adequacy and accuracy of the contents herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230630370339/en/

Biomind Labs Inc.
Alejandro Antalich
Chief Executive Officer
Email: info@biomindlabs.com
Tel: + 598 97 702500